ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2013
Recent insights into C3 glomerulopathy.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 79 citations in OpenAlex.
- Relationship of gene polymorphisms for complement components C3 and factor H and kidney allograft function.BMC nephrology · 2025Observational
- IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study.BMC nephrology · 2023Article
- Comparison of dominant and nondominant C3 deposition in primary glomerulonephritis.Kidney research and clinical practice · 2023Article
- C3 glomerulopathy associated with both hypertensive retinopathy and purtscher-like retinopathy.American journal of ophthalmology case reports · 2022Article
- Review
- Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.Transgenic research · 2021Article
- Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.Antioxidants (Basel, Switzerland) · 2021Review
- Genetic and pathological findings in a boy with psoriasis and C3 glomerulonephritis: A case report and literature review.Molecular genetics & genomic medicine · 2020Review
- Clinicopathological features of C3 glomerulopathy in children: a single-center experience.Pediatric nephrology (Berlin, Germany) · 2020Article
- Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.Frontiers in immunology · 2020Review
- Complement and Complement Targeting Therapies in Glomerular Diseases.International journal of molecular sciences · 2019Review
- Dense deposit disease: a greatly increased biopsy incidence in India versus the USA.Clinical kidney journal · 2019Article
- Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.Clinical and experimental nephrology · 2019Article
- Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Predictive factors for poor outcome in pediatric C3 glomerulonephritis.Fukushima journal of medical science · 2018Article
- Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.Journal of the American Society of Nephrology : JASN · 2018Article
- An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.Journal of the American Society of Nephrology : JASN · 2018Article
- Treating C3 glomerulopathy with eculizumab.BMC nephrology · 2018Article
- Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.Kidney international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
'C3 glomerulopathy' is a recent disease classification comprising several rare types of glomerulonephritis (GN), including dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and CFHR5 nephropathy. These disorders share the key histological feature of isolated complement C3 deposits in the glomerulus. A common aetiology involving dysregulation of the alternative pathway (AP) of complement has been elucidated in the past decade, with genetic defects and/or autoantibodies able to be identified in a proportion of patients. We review the clinical and histological features of C3 glomerulopathy, relating these to underlying molecular mechanisms. The role of uncontrolled C3 activation in pathogenesis is emphasized, with important lessons from animal models. Methods, advantages and limitations of gene testing in the assessment of individuals or families with C3 glomerulopathy are discussed. While no therapy has yet been shown consistently effective, clinical evaluation of agents targeting specific components of the complement system is ongoing. However, limits to current knowledge regarding the natural history and the appropriate timing and duration of proposed therapies need to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.